Eli Lilly and Company
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Eli Lilly and Company
- Company name
- Eli Lilly and Company
- Organisation type
- Industry
- Registered legal name
- ELI LILLY & Co
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- SEC filer number (CIK)
- 0000059478
Related records
Trials (2,873)
- (CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer
- [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
- 12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
- 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
- 2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis
- 24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine
- 24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
- 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
- 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
- 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
- A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease
- A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
- A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects
- A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
- A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
- A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
- A Bioavailability Study of LY2452473 and Tadalafil
- A Bioequivalence (BE) Study in Healthy Subjects
- A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants
- A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants